These considerations may provide guidelines for predicting the extent to which different kinds of tumour cells, particularly those which over-express eIF4E or have deregulated PI3K, Akt or mTOR activity, are likely to respond to the new generation of mTOR inhibitors and eIF4F disrupting agents that are now being developed for use in cancer therapy [44], [61]–[63]. The gene discussed is AKT1; the disease is cancer.